Pharmacological subgroup
H01C – HYPOTHALAMUSHORMONE
6Decisions
7Patient groups
Added benefit by patient group
- Considerable1
- Minor2
- Not proven4
Subgroups
- H01CB Somatostatin und Analoga 2 decisions
- H01CC Gonadotropin-Releasing-Hormonantagonisten 4 decisions
Decisions, newest first
- 2025-06-05YseltyLinzagolixNot proven
- 2025-03-06YseltyLinzagolixNot proven
- 2024-05-16RyeqoRelugolix/Estradiol/NorethisteronNot proven
- 2022-02-17RyeqoRelugolix/Estradiol/NorethisteronConsiderable: 1 of 2 patient groupsNot proven: 1 of 2 patient groups
- 2015-06-18SigniforPasireotidMinor
- 2012-12-06SigniforPasireotidMinor
Data status: 2026-10-29